New contraindications and modified cardiovascular parameters for fingolimod Full Text
Formulary , 07/11/2012
FDA announced completion of their safety review of fingolimod (Gilenya, Novartis), an oral agent approved in September for the treatment of relapsing forms of multiple sclerosis. The safety review was initiated after a report of a patient who died within 24 hours of taking the first dose of fingolimod.



